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Aims To assess the prognostic value of anti-apolipoprotein A-1 (anti-apoA-1) IgG after myocardial infarction (MI) and its
association with major cardiovascular events (MACEs) at 12 months and to determine their association with resting
heart rate (RHR), a well-established prognostic feature after MI. Anti-apoA-1 IgG have been reported in MI without
autoimmune disease, but their clinical significance remains undetermined.
Methods
and results
A total of 221 consecutive patients with MI were prospectively included, and all completed a 12-month follow-up.
Major cardiovascular events consisted in death, MI, stroke, or hospitalization either for an acute coronary syndrome
or heart failure. Resting heart rate was obtained on Holter the day before discharge under the same medical treat-
ment. Neonate rat ventricular cardiomyocytes (NRVC) were used in vitro to assess the direct anti-apoA-1 IgG effect
on RHR. During follow-up, 13% of patients presented a MACE. Anti-apoA-1 IgG positivity was 9% and was associated
with a higher RHR (P ¼ 0.0005) and higher MACE rate (adjusted OR, 4.3; 95% CI, 1.46–12.6; P ¼ 0.007). Survival
models confirmed the significant nature of this association. Patients with MACE had higher median anti-apoA-1
IgG values at admission than patients without (P ¼ 0.007). On NRVC, plasma from MI patients and monoclonal
anti-apoA-1 IgG induced an aldosterone and dose-dependent positive chronotropic effect, abrogated by apoA-1
and therapeutic immunoglobulin (IVIG) pre-incubation.
Conclusions In MI patients, anti-apoA-1 IgG is independently associated with MACE at 1-year, interfering with a currently
unknown aldosterone-dependent RHR determinant. Knowing whether anti-apoA-1 IgG assessment could be of inter-
est to identify an MI patient subset susceptible to benefit from apoA-1/IVIG therapy remains to be demonstrated.
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Immune-mediated inflammation plays a major role in atherosclero-
sis and atherothrombosis, two essential features for cardiovascular
disease (CVD) development, currently considered as the leading
cause of death in the Western world, and predicted to be the
first killer by 2020.1,2 At a time where the incidence of CVD is
increasing,2 the research of new and modifiable cardiovascular
factors is highly warranted. Those efforts are meant to identify a
new CVD patient subset potentially susceptible to benefit from
innovative therapeutic approaches. To this respect, there is an
accumulating evidence showing that humoral autoimmunity might
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play an important role in CVD3,4 and that some auto-antibodies
could represent emerging cardiovascular risk factors,5– 9 poten-
tially modifiable by passive immunization.10
Lately, we reported that IgG auto-antibodies against apolipopro-
tein A-1 (apoA-1), the major proteic fraction of high-density lipo-
protein (HDL), were present in a significant subset of patients after
myocardial infarction (MI)11,12 and were significantly associated to
higher levels of circulating oxidized low-density lipoproteins
(oxLDLs),12 a major player of atherogenesis.13– 15 However, the
clinical and pathophysiological significance of anti-apoA-1 IgG
remains unknown. The present study was performed to assess
their prognostic value in MI and to determine their association
with resting heart rate (RHR), a well-established cardiovascular
prognostic feature after MI.16 –19 To this respect, some auto-
antibodies have been shown to interfere with the heart rate con-
duction system function in humans,20 supporting the growing
number of observation showing that humoral autoimmunity may
play a role in the autonomic nervous system dysfunction impair-
ment commonly observed in autoimmune diseases.21 Therefore,
we investigated whether anti-apoA-1 IgG could directly influence
autonomous contractions in vitro using spontaneously beating
neonate rat ventricular cardiomyocytes (NRVC) in which minera-
locorticoid activation has been shown to induce a positive chron-
otropic effect through the expression of low threshold T-type
calcium channels22 –24 and of hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels.25
Methods
The research ethic committee of Geneva University Hospitals
approved the protocol, and all patients gave written informed
consent before enrolment.
Patient population and study design
The sample size was computed based on an expected prevalence of
apoA-1 IgG in acute coronary syndrome (ACS) of 11%.12 A total
sample size of 220 patients was needed to detect a three-fold increase
in the risk of a major event (12 vs. 36%) with a power of 80% with an
alpha error of 5%.
Between 1 November 2005 and 30 June 2007, 366 consecutive
patients were screened at the emergency room (ER) and intensive
care unit (ICU) of Geneva University Hospital for an MI, commonly
defined by typical clinical presentation associated with or without ST
elevation, with subsequently proven angiographic coronary stenosis
needing percutaneous coronary intervention, or associated with
cardiac necrosis biomarkers elevation. Significant coronary artery
disease (CAD) was defined as a culprit lesion obstructing more than
75% of the vessel lumen on coronary angiography. Such lesions
were found in 98% of cases. However, when no significant culprit
lesion was found upon coronary angiography despite typical clinical
presentation associated with a rise of biochemical markers of cardiac
necrosis, patients were included in the present study (four patients).
Exclusion criteria were Takotsubo disease, the presence of any
known auto-immune disease except diabetes mellitus, and inability
to give informed consent for any reason, including oro-tracheal
intubation.
Among the 366 screened patients, 145 met exclusion criteria,
leaving 221 patients available for the analysis. Conventional left ventri-
cular ejection fraction evaluation by echocardiography was performed
within 5 days of admission by experienced cardiologists, blinded to the
biochemical results.
Resting heart rate was assessed as mean heart rate on 24 h record-
ing (Holter) the day before patients’ discharge. At the time of record-
ing, all patients were treated with statins, angiotensin-converting
enzyme inhibitors or angiotensin-receptor blocker, beta-blockers,
aspirin, and clopidogrel. None was under aldosterone antagonist
therapy.
Definition of endpoint
Major cardiovascular events (MACEs) were predetermined and con-
sisted in any death, MI, stroke, or hospitalization for ACS or acute
heart failure at 1 year.
Patient follow-up
All patients completed the 12-month follow-up. Outcome was inde-
pendently adjudicated by two of the study coordinators (E.C., R.N.)
who were blinded to the results of biochemical analyses. Information
was obtained by contacting patients by telephone and was further con-
firmed by checking patients’ medical file and contacting the physician in
charge of the patient, targeting medical history relevant to the study
endpoints.
Sample collection
To avoid interference with the door-to-revascularization policy,
samples were taken after percutaneous coronary intervention within
the first 24 h of hospitalization. After collection, serum samples
were aliquoted and frozen at 2808C until analyses. Data were col-
lected from patients’ files in the ER and ICU.
Biochemical analysis
Determination of human antibodies to apoA-1
by enzyme-linked immunosorbent assay
Anti-apoA-1 IgG were measured as described previously.12 The speci-
ficity of the detection was assessed using conventional saturation tests
described before11,12 and further confirmed by western blot (data not
shown).
Intra- and inter-assay variations
Repeatability and reproducibility were determined at two levels. At a
high level (two-fold the cut-off value), the coefficients of variation
were 10% (n ¼ 10) and 17% (n ¼ 10) for intra and inter-assay, respect-
ively. At the cut off-level, the coefficients of variation were 16% (n ¼
10) and 12% (n ¼ 8) for intra and inter-assay, respectively.
Reference values
As described earlier, upper reference value was set at an absorbance
of 0.6 optical densities (OD), corresponding to the 97.5th percen-
tile of a reference population established on 140 healthy blood
donors.12 In order to limit the impact of interassay variation, we devel-
oped an index consisting in the ratio between sample net absorbance
and the positive control net absorbance  100. The value correspond-
ing to the 97.5th percentile of the normal distribution was 37 for the
index. Accordingly, to be considered as positive, samples had to
display an absorbance value above 0.6 OD and an index above 37.
Classical autoantibody measurement
Anti-nuclear antibody (ANA) and rheumatoid factor (RF) measure-
ments were performed in the clinical laboratory for immunology and
allergy of the University Hospital of Geneva, using routine indirect
immunofluorescence and enzyme-linked immunosorbent assay
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(ELISA) techniques. IgG and IgM auto-antibodies to b2 glycoprotein I
(anti-b2GPI) and cardiolipin were measured by ELISA as previously
described.26 All 221 patients were tested negative for ANA, 1 was
positive for RF, but 20 (9%) of them were positive either for anti-
b2GPI or anti-cardiolipin antibodies. Among those, three were conco-
mitantly positive for anti-apoA-1 IgG and anti-cardiolipin antibodies.
Patients tested positive for anti-apoA-1 IgG were all negative for anti-
b2GPI antibodies.
Cardiac troponin I, creatin kinase, N-terminal pro brain
natriuretic peptide (NT-proBNP), C-reactive protein,
creatinin, total cholesterol, triglycerids, and high-density
lipoprotein quantification
Cardiac troponin I (cTnI) concentrations were determined on Unicell
DXI 800TM (Beckman Coulter, Brea, CA, USA). Creatin kinase (CK),
C-reactive protein, creatinin, total cholesterol, triglycerids, and HDL
(mmol/L) were determined using a Synchron LX20 proTM (Beckman
Coulter) auto-analyser, and NT-proBNP was determined using
ElecsysTM (Roche, Switzerland) automate.
Cell culture and cell contraction frequency
Neonatal cardiac cells were isolated from 1- to 2-day-old Wistar rat ven-
tricles by digestion with low trypsin-EDTA and type 2 collagenase as
described previously.22–24 Briefly, animals were killed (in conformity
with the Guide for the Care and use of Laboratory Animals published
by the NIH and with the authorization (31.1.1012/19s3/0) of the local
County Veterinary Office) and freshly isolated cells were seeded in
plastic flasks to allow selective adhesion of cardiac fibroblasts. Thereafter,
cardiomyocytes were decanted from the flasks and distributed in laminin-
coated 90-mm Petri dishes or in 6-well culture plates. Cells from a same
preparation were used for testing the various experimental conditions.
Spontaneously contracting cell monolayers were incubated for the
indicated times with a 10% dilution of MI patients plasma or reference
plasma spiked with different concentrations (1–20 mg/mL) of mouse
monoclonal anti-human apoA-1 IgG (Abcam, Nottingham, UK) and
respective IgG controls (polyclonals) of the same genetic background
(Meridian Life Science, Cincinnati, OH, USA) in serum-free DMEM.
Ultra-pure lipid low apoA-1 was provided by R. James and intravenous
immunoglobulins (IVIG; EndobulinTM) were purchased from Baxter
(Switzerland, Volketswil). Cell beating frequency was determined by
counting, under light microscope, the number of contractions per
time unit in three different locations of the dish. Those tests were per-
formed after 24 h pre-incubation of cells in serum-free medium with
and without aldosterone (10 nM) by an observer blinded to
anti-apoA-1 IgG sample status. Results are expressed in beat per
minute (b.p.m.). Experiments were also performed with addition of
antibodies directly into serum-free culture medium.
Statistics
Analyses were performed using StatisticaTM software (StatSoft, Tulsa,
OK, USA). Fischer exact test, x2 using Yates correction test, and
Mann–Whitney U-test were used when appropriate to compare the
group of patients. Spearman test was used to assess correlation
between variables. Associations between anti-apoA-1 IgG and compo-
site cardiovascular outcome are presented as odds ratios (OR) with
corresponding 95% confidence intervals (95% CI) and using Kaplan–
Meier analysis and Cox regression model. Two-sided P-value was
considered as significant when below 0.05. For in vitro experiments,
Mann–Whitney U-test has been used to determine P-values unless
stated otherwise, and results are expressed as median, interquartile
range, and range.
Results
Demographic characteristics
Patient demographic characteristics are listed in Table 1. The fre-
quency of positive anti-apoA-1 IgG auto-antibodies was 9% (19
of 221) and 14% (31 of 221) of patients had a MACE during the
1-year follow-up (Table 1).
High levels of anti-apoA-1 IgG are
associated with major cardiovascular
events at 1 year
One year after the initial event, 31 patients (14%) experienced a
MACE. The detailed distribution of MACEs is given in Table 1.
Among the three patients died, one patient died from cardiorespira-
tory arrest, one from abdominal aorta aneuvrysm rupture, and one
from septic shock. On the 19 patients hospitalized for ACS, 10 had a
proven MI, and 9 were diagnosed with unstable angina, of whom 5
presented significant angiographic coronary lesion. The remaining
nine patients were hospitalized for acute heart failure. No patient
had a clinically evident stroke during this 1-year follow-up period.
Patients with MACEs had higher median anti-apoA-1 IgG titre
upon admission than patients without MACEs (31.4 vs. 20.6 OD;
P ¼ 0.004). Complication rate was 37% in patient tested positive
for anti-apoA-1 IgG against 12% in patients tested negative for
those auto-antibodies, corresponding to a four-fold increase in
risk of MACEs (OR, 4.3; 95% CI, 1.54–11.99; P ¼ 0.008), which
remained unchanged after adjustment for age, sex, hypertension,
diabetes, dyslipidaemia, smoking (OR, 4.3; 95% CI, 1.46–12.6; P ¼
0.007). Kaplan–Meier analysis confirmed that patients positive for
anti-apoA-1 IgG upon admission had a significantly worse
complication-free survival at 1 year than those tested negative for
those auto-antibodies (63.2 vs. 88.5%, P ¼ 0.001; Figure 1). Cox
regression analysis showed that each unit increase of anti-apoA-1
IgG relative index increased the risk of complication at 1 year by
3% (P ¼ 0.0003), independently of time (P ¼ 0.39), confirming the
proportionality principle of the model.
Anti-apoA-1 IgG positivity is associated
with elevated resting heart rate
in myocardial infarction patients
As shown in Table 1, MI patients positive for anti-apoA-1 IgG had
higher median RHR than those tested negative and Spearman test
showed a modest, but significant, correlation between RHR of
patients before discharge and the titre of anti-apoA-1 IgG on the
whole cohort (r ¼ 0.18, P, 0.025). No association was retrieved
between apoA-1, C-reactive protein levels, and RHR according to
Spearman test (data no shown).
Positive chronotropic action
of anti-apoA-1 IgG in vitro
We then tested in vitro the chronotropic action of anti apo-A1 IgG
on freshly isolated NRVC that share some properties with cardiac
pacemaker cells. Indeed, these cells maintain their ability (acquired
during the foetal development) to contract spontaneously in
culture and aldosterone increases their beating frequency.22 We
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Table 1 Patients demographic characteristics
MI patients (n5 221) MI patients negative for
anti-apoA-1 IgG
(n 5 202)
MI patients positive for
anti-apoA-1 IgG (n 5 19)
P-value
Age, years 64 (26–86; 55–74) 64 (28–86; 55–74) 62 (26–86; 54–72) 0.65
Sex
Male, % (n) 78 (173) 77 (156) 89 (17) 0.38
Female, % (n) 22 (48) 23 (46) 11 (2)
BMI, kg/m2 25.8 (18–39.5; 24–29) 26 (17–39; 24–28) 25 (18–39.5; 21–32) 0.63
Creatinin, mmol/L 84 (47–275; 73–98) 84 (47–275; 73–97) 93 (62–211; 73–106) 0.20
C-reactive protein, mg/L 6 (1–230; 14–39) 6 (1–230; 3–14.2) 7.2 (1–96; 2.8–13) 0.76
cTnI, ng/mL 0.5 (0–153; 5–7) 0.4 (0.15–3; 0.1–3) 1.0 (0–80; 0.1–10) 0.29
CK peak, IU/L 687 (273–751; 1410–1783) 687 (41–7511; 264–1785) 573 (77–3252; 281–1308) 0.79
NT-proBNP, pg/mL 785 (20–28 285; 283–2057) 778 (36–28 285; 289–2157) 885 (20–14 205; 125–1842) 0.66
Lipid profile, mmol/L
Total cholesterol 4.8 (1.9–11.8; 4–5.8) 4.9 (1.9–8.8; 4.1–5.8) 4.8 (3.2–11.8; 3.9–6) 0.94
HDL 1.06 (0.5–2.7; 0.9–1.3) 1.05 (0.5–2.7; 0.9–1.3) 1.1 (0.7–1.7; 0.9–1.4) 0.35
LDL 3.1 (0.5–4; 2.4–3.9) 3.2 (0.5–7; 2.4–3.9) 2.9 (1.8–9.5; 2.4–4.3) 0.86
Triglycerids 1.1 (0.5–7.3; 0.8–1.7) 1.1 (0.1–7.3; 0.8–1.7) 0.9 (0.4–2.3; 0.6–1.5) 0.22
Comorbidities, % (n)
Hypertension 53 (117) 53 (108) 47 (9) 0.63
Diabetes 19 (43) 20 (40) 16 (3) 1
Dyslipidaemia 46 (102) 47 (94) 42 (8) 0.81
Smoker 45 (99) 45 (91) 42 (9) 1
Known CAD 29 (65) 29 (58) 32 (6) 0.79
Stroke 5 (12) 4 (8) 21 (4) 0.01
Positive familial history 31 (69) 31 (62) 37 (7) 0.6
Atrial fibrillation 5 (11) 4 (9) 11 (2) 0.24
STEMI, % (n) 54 (120) 53 (108) 63 (12) 0.48
NSTEMI, % (n) 46 (101) 47 (94) 37 (7)
LVEFa, % 50 (20–60; 10) 50 (25–60; 45–55) 45 (20–60; 40–60) 0.33
Resting heart rate at discharge, b.p.m. 68 (50–120; 15) 67 (50–97; 60–72) 76 (56–120; 70–90) 0.0005
MACE rate at 12 months, % (n) 14 (31) 12 (24) 37 (7) 0.008
MACE details: deaths 1 (3) 1 (3) 0 (0) 1
ACS 9 (19) 7 (14) 26 (5) 0.01
Heart failure 4 (9) 3 (7) 11 (2) 0.17
Stroke 0 0 0 —
Anti-phospholipid antibody positivity rate, % (n) 10 (22) 9 (19) 16 (3) 0.41
Medication at inclusion, % (n)
Aspirin 32 (71) 32 (65) 32 (6) 1
Clopidogrel 16 (25) 11 (23) 11 (2) 1
b-Blocker 28 (61) 27 (55) 32 (6) 0.78
ACE or AT1 inhibitors 39 (86) 38 (77) 47 (9) 0.46
Statin 35 (77) 35 (71) 32 (6) 1
Diuretics (excluding amiloride and MR
antagonists)
19 (43) 19 (39) 22 (4) 0.76
Anti-diabetic agents 12 (27) 12 (25) 11 (2) 1
Insulin 7 (16) 7 (14) 11 (2) 0.63
All continuous variables are reported as median with (range and interquartile range). P-value was calculated according to Mann–Whitney U-test for continuous variable and
according to exact bilateral Fischer test for proportions.
ACS, acute coronary syndrome; ACE, angiotensin-converting enzyme; AT1, angiotensin II receptor type 1; LVEF, left ventricular ejection fraction.
aAvailable in 90% of patients.
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observed that addition of monoclonal mouse anti-human apoA-1
IgG, spiked in reference plasma or culture media, significantly
increased the basal contraction rate of cardiomyocytes in a
concentration-dependent manner. The maximal response was
observed at a concentration of 10 mg/mL (Figure 2A). At this
optimal concentration, the effect was statistically significant when
compared with reference plasma alone and with reference
plasma spiked with control IgG (78 vs. 27.5 b.p.m., P ¼ 0.01; and
78 vs. 38 b.p.m., P ¼ 0.004; respectively; Figure 2B). This chrono-
tropic effect was not seen when anti-apoA-1 IgG was applied to
naı¨ve cells, not primed with aldosterone (Figure 2B) or primed
with other steroids than aldosterone (data not shown).
The same experiments were repeated using plasma samples
obtained from MI patients. Fifteen plasmas from MI patients
tested positive for anti-apoA-1 IgG and 15 plasmas from MI
patient samples that were negative for those antibodies were ran-
domly taken. Myocardial infarction plasma positive for anti-apoA-1
IgG induced a significantly higher median increase of cardiomyo-
cyte contraction rate than patient plasma negative for anti-apoA-1
IgG (95 vs. 62 b.p.m.; P ¼ 0.04, Figure 2C). When expressed in per-
centage of baseline to normalize for the baseline variability (30 vs.
36 b.p.m., Figure 2C), Spearman test showed a significant corre-
lation between the titre of anti-apoA-1 IgG and cardiomyocyte
contraction rate (r ¼ 0.45, P ¼ 0.02), confirming the dose-
dependent relationship between anti-apoA-1 IgG in MI plasma
and basal heart rate.
Figure 1 Kaplan–Meier time-to-events plot for cardiovascular
outcome at 1 year according to anti-apoA-1 IgG status.
Figure 2 (A) Dose-dependent chronotropic effect of
anti-apoA-1 IgG in vitro. Results are expressed as median with
interquartile range and range. *P ¼ 0.01 according to Kruskall–
Wallis test. **P ¼ 0.7 according to Kruskall–Wallis test. (B)
Aldosterone-dependent effect of anti-apoA-1 IgG in vitro. * and
**P ¼ 0.004. Results are expressed as median with interquartile
range and range. (C) Effect of myocardial infarction plasma on
in vitro contraction rate according to anti-apoA-1 IgG status.
*P ¼ 0.2 and *P ¼ 0.04. Results are expressed as median with
interquartile range and range.
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Anti-apoA-1 IgG chronotropic effect on
cardiomyocytes is idiotype-dependent
and abolished by therapeutic
immunoglobulin
The chronotropic response was almost fully abolished when
anti-apoA-1 IgG was added together with 1 mg/mL of delipidated
apoA-1, demonstrating the idiotype specificity of the anti-apoA-1
IgG effect on cardiomyocyte contraction rate (Figure 3A). This posi-
tive chronotropic effect was also strongly abrogated by IVIG 2 mg/
mL (Figure 3B). ApoA-1 per se displayed a modest, but significant,
positive chronotropic effect on contraction rate when compared
with baseline (Figure 3A, P ¼ 0.03), whereas IVIG per se did not
(Figure 3B, P ¼ 1).
Discussion
The novel and important finding of the present study is that
anti-apoA-1 IgG appears as a new prognostic marker of MACEs
1 year after MI, independently of traditional cardiovascular risk
factors, but associated with RHR, another major cardiovascular
prognostic feature after MI.16– 19 Elevated RHR is known to
affect the cardiovascular risk by concomitantly increasing myocar-
dial oxygen demand while decreasing its supply27 and energy
stores,28 accelerating atherosclerosis,29 –31 and enhancing plaque
vulnerability.32 Although RHR following MI has been considered
as a prognostic factor since more than two decades,17 the
recent results of the BEAUTIFUL study allowed determining a
reasonable but arbitrary RHR cut-off above which the risk of car-
diovascular complications is drastically increased and set at 70
b.p.m.16 To this respect and even if our patients had a higher
median EF than the patients enrolled in the BEAUTIFUL study, it
is interesting to note that MI patients who were positive for
anti-apoA-1 IgG had RHR above this threshold (median value of
76 b.p.m.), whereas MI patients tested negative for these antibodies
were below the threshold (median value of 67 b.p.m., P ¼ 0.0005).
Moreover, plasma of MI patients containing high levels of
anti-apoA-1 IgG induced in vitro a significant increase of the basal
rat cardiomyocytes beating frequency that was more pronounced
than the response to plasma without these auto-antibodies (95 vs.
62 b.p.m., P ¼ 0.04). Together with the dose-dependent effect of
anti-apoA-1 IgG at physiologically relevant concentrations (1–
20 mg/mL), the significant positive correlations between
anti-apoA-1 IgG titre with RHR both in vivo and in vitro strongly
suggest that the presence of anti-apoA-1 IgG is responsible for
the positive chronotropic effect of MI plasma, which was reverted
by physiologically relevant concentrations of IVIG and apoA-1.
Both IVIG and apoA-1 have been reported as promising CVD
therapeutic modalities in mice, but data in humans are
scarce,33–35 Therefore, knowing whether anti-apoA-1 IgG-positive
MI patients could specifically benefit from IVIG or apoA-1 treat-
ment remains highly speculative at the present time, and
further work is needed to determine whether anti-apoA-1 IgG is
a cardiovascular risk factor or just a marker of cardiovascular risk.
Our results raise several questions. To the best of our knowl-
edge, apoA-1, the antigen against which those auto-antibodies
are directed to, is not known to be expressed by rat
cardiomyocytes. Accordingly, one can evoke a non-specific effect
of those antibodies or even serendipity. However, given the
absence of effect of the negative controls, and the concentration-
dependency of the response, it is more reasonable to evoke mol-
ecular mimicry between a common conformational epitope shared
by cardiomyocytes and apoA-1 to account for the aforementioned
observations. More importantly, the complete reversion of
anti-apoA-1 IgG effect by a saturation test using apoA-1 is the
strongest argument, indicating that the chronotropic effect
observed was idiotype-dependent, lending further weight to the
molecular mimicry hypothesis. To this respect, the fact that the
effect was observed only aldosterone incubation raises several
mutually non-exclusive hypotheses about the nature of this
epitope. First, since aldosterone is known to increase T-type
calcium as well as HCN channels expression and function, which
translated into a significant increase in cardiomyocyte contraction
rate,22–25 it is possible that anti-apoA-1 IgG could interfere with
one of those channels function, whose relevance in cardiovascular-
related physiopathology is well documented in humans.16,36,37 or
with other signalling components induced by the mineralocorticoid
receptor. Ongoing in vitro pharmacological and electrophysiological
Figure 3 (A) Idiotype-dependent chronotropic effect of
anti-apoA-1 IgG. (B) Inhibition of anti-apoA-1 IgG chronotropic
effect by IVIG. * and **P ¼ 0.01. Results are expressed as
median with interquartile range and range.
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studies will resolve those matters. Another non-exclusive hypoth-
esis could be that those autoantibodies might also interfere with
more classical apoA-1-related properties, such as reverse choles-
terol transport, anti-inflammatory, or anti-oxidant activities,
which in turn might negatively affect atherogenesis and plaque
stability.
Despite being appropriately powered, the number of events in
this study is still relatively low, preventing us to draw definite con-
clusions at the present time and those results need to be repro-
duced before any clinical recommendation can be made.
However, as the rate of cardiovascular complications at 12
months was similar to the one observed in another bigger study
(14 vs. 15%) using similar endpoints,16 we consider our sample
to be representative of MI pathology. Also, it is noteworthy that
3 of the 19 patients positive for anti-apoA-1 IgG were also positive
for anti-cardiolipin IgG, but not for other anti-b2GP1 autoanti-
bodies, ANA or RF. Even if none of these patients were known
for any other autoimmune disease, we cannot exclude the conco-
mitant presence of anti-cardiolipin in these samples, as cross reac-
tivity between anti-apoA-1 IgG and anti-cardiolipin antibodies has
been described.38 Because anti-cardiolipin antibodies were not
associated with patients’ outcome in this study (data not shown),
we believe that the reported herein associations are not clouded
by a cross-reactivity confounder. The strength of this study
resides in the fact that the prognostic value of those anti-apoA-1
IgG auto-antibodies has been confirmed in three different statisti-
cal models (multivariate logistic regression, Kaplan–Meier analysis,
and Cox regression) and that we were able to reproduce robustly
the reported association found on this cohort using a relevant in
vitro model, which provides a mechanistic hypothesis to explain
the herein reported prognostic aspect of anti-apoA-1 IgG after MI.
Conclusions
We report anti-apoA-1 IgG as a novel potential prognostic bio-
marker for MACEs in patients in post-MI period, independently
of traditional cardiovascular factors (age, sex, hypertension, dia-
betes, dyslipidaemia, and smoking), but significantly associated
with increased RHR, a major adverse prognostic factor after MI.
The exact chronotropic mechanisms of those auto-antibodies
are not known. Whether anti-apoA-1 IgG could represent a new
and potentially modifiable cardiovascular factor after an MI, or
just a risk marker, remains to be demonstrated in other larger
trials.
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Non-invasive diagnosis of chylopericardium by cardiac magnetic
resonance imaging
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A 24-year-old woman was admitted to the hospital
because of massive persistent asymptomatic pericar-
dial effusion. Six months earlier, she had visited her
rheumatologist because of polyarthralgias suggesting
systemic lupus erythematosus. She had never com-
plained of dyspnoea or cough. On echocardiography,
a large, homogeneous pericardial effusion, ‘swinging
heart’-type, was found (see Supplementary material,
Movie I), with no signs of haemodynamic compro-
mise (Panels A, parasternal long axis, and B, apical
four-chamber with severe pericardial effusion
[arrow]). A cardiac magnetic resonance imaging
(CMR) was performed revealing a massive pericar-
dial effusion (see Supplementary material, Movies II
and III). No fibrous tracts were detected. Black
blood images without (Panel C) and with fat satur-
ation techniques (Panel D) were acquired and
the suppression of the signal intensity of the fluid
(asterisks) suggested the presence of fat in it. Pericardiocentesis was planned based on CMR images, obtaining 1 L of dense, intensely
chylous fluid. A chemistry analysis revealed a triglyceride level of 3700 mg/dL. Cytology and cultures yielded negative results. Follow-up
MRI and chest computed tomography performed 1 month later showed recurrence of the effusion and findings compatible with lupus
pneumonitis, while the patient remained asymptomatic. She was referred for surgery, which included drainage of the chylopericardium,
ligation of the thoracic duct, and biopsy of the pericardium, which yielded unspecific results.
In conclusion, CMR is the only non-invasive technique capable of giving the diagnosis of chylopericardium, since it provides a biochemi-
cal characterization of pericardial effusion. In clinically stable patients, CMR can be helpful in further diagnosis of pericardial effusion.
Supplementary material is available at European Heart Journal online.
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